Wholesales ethical pharmaceuticals, diagnostic reagents, and medical devices to hospitals, clinics, and dispensing pharmacies. Now — the numbers.
This is an established company with proven profits.
No real growth (5% a year).
If every debt were paid off today, $1.0B would still be left in the vault — a solid cushion for hard times.
The market pays 9× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 25% below its peak. The market has trimmed its expectations for the company.
There is $1.3B in the vault; even if every debt were paid off, $1.0B would remain.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.